Medicare AdvantagePrior AuthMedium impact
Intravenous tocilizumab products (Revised)
Humana·Rheumatology, Oncology, Pediatrics +1 more·Medicare Advantage
Effective date
Jun 24, 2026
We identified it
Jul 1, 2026
Summary
Humana Medicare Advantage updated its intravenous tocilizumab prior authorization policy (effective January 1, 2019; revised June 24, 2026). The policy covers four tocilizumab products (Actemra, Tyenne, Tofidence, Avtozma) for five FDA-approved indications: moderately to severely active rheumatoid arthritis (with prior DMARD therapy requirement), systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, cytokine release syndrome, and giant cell arteritis. Key exclusion: combination therapy with other biologics is not covered. Prior authorization is required for all covered indications.
Action Required
Before June 24, 2026: (1) Billing and Prior Authorization teams must update their authorization protocols to enforce the revised step therapy requirements for intravenous tocilizumab products on Medicare Advantage plans. (2) Specifically, for rheumatoid arthritis patients ≥18 years, require documentation of prior therapy, contraindication, or intolerance with Remicade, Inflectra, Infliximab, or Simponi Aria before approving Actemra, Tyenne, Tofidence, or Avtozma—exception: if continuation of prior therapy within past 365 days. (3) For SJIA and polyarticular JIA (patients ≥2 years), require active diagnosis documentation. (4) For CAR T-cell induced CRS (patients ≥2 years), verify severe or life-threatening CRS diagnosis. (5) For giant cell arteritis (patients ≥18 years), verify diagnosis documentation. (6) REJECT all claims combining tocilizumab with biologics (Cosentyx, Enbrel, adalimumab, Kevzara, Remicade). (7) Update prior authorization request forms and billing system rules to enforce these exclusions. (8) Train clinical staff on age requirements and indication-specific criteria. Failure to apply these requirements will result in denials and appeal rework.